OTCMKTS:EPRSQ - EPIRUS Biopharmaceuticals Stock Price, Price Target & More

$0.0030 0.00 (0.00 %)
(As of 04/24/2018 02:26 PM ET)
Previous Close$0.0030
Today's Range$0.0030 - $0.0030
52-Week Range$0.0003 - $0.02
Volume40,601 shs
Average Volume32,176 shs
Market Capitalization$80,000.00
P/E RatioN/A
Dividend YieldN/A
Beta1.19

About EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:EPRSQ
CUSIPN/A
Phone617-600-3497

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$580,000.00
Price / Sales0.14
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares26,180,000

How to Become a New Pot Stock Millionaire

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

What is EPIRUS Biopharmaceuticals' stock symbol?

EPIRUS Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How were EPIRUS Biopharmaceuticals' earnings last quarter?

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) issued its quarterly earnings data on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.07. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $0.41 million. View EPIRUS Biopharmaceuticals' Earnings History.

Who are some of EPIRUS Biopharmaceuticals' key competitors?

Who are EPIRUS Biopharmaceuticals' key executives?

EPIRUS Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jeff Kagy, VP of HR & Admin.
  • Mr. Robert Ticktin, Sr. VP, Gen. Counsel and Sec. (Age 56)
  • Jason Yap, Head of Global Regulatory Affairs and Sr. Director
  • Dr. Louis Boon Ph.D., Head of CLG, Bioassay & Process Devel.
  • Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD

Has EPIRUS Biopharmaceuticals been receiving favorable news coverage?

News coverage about EPRSQ stock has trended somewhat positive on Tuesday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EPIRUS Biopharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.28 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of EPIRUS Biopharmaceuticals?

Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EPIRUS Biopharmaceuticals' stock price today?

One share of EPRSQ stock can currently be purchased for approximately $0.0030.

How big of a company is EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals has a market capitalization of $80,000.00 and generates $580,000.00 in revenue each year.

How can I contact EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]


MarketBeat Community Rating for EPIRUS Biopharmaceuticals (EPRSQ)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about EPIRUS Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Consensus Price Target History

Price Target History for EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/16/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details
(Data available from 4/24/2016 forward)

Earnings

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings History and Estimates Chart

Earnings by Quarter for EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q1 2016($0.53)($0.66)$2.00 million$0.80 millionViewN/AView Earnings Details
3/15/2016Q415($0.56)($0.63)$0.41 million$0.29 millionViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)$0.40 million$0.05 millionViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)$0.68 million$0.03 millionViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
8/11/2014Q2 2014($1.20)($1.52)$1.50 million$1.13 millionViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)$3.20 million$3.77 millionViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 million$3.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
11/8/2012Q3 2012($5.40)($6.00)ViewN/AView Earnings Details
8/7/2012Q2 2012($6.60)($5.46)ViewN/AView Earnings Details
5/3/2012Q1 2012($6.60)($7.20)ViewN/AView Earnings Details
3/7/2012Q4 2011($6.00)($6.00)ViewN/AView Earnings Details
11/2/2011Q3 2011($6.00)($5.58)ViewN/AView Earnings Details
8/3/2011Q2 2011($5.40)($6.84)ViewN/AView Earnings Details
5/4/2011Q1 2011($5.40)($7.20)ViewN/AView Earnings Details
3/9/2011Q4 2010($7.20)($8.04)ViewN/AView Earnings Details
11/10/2010Q3 2010($6.60)($4.56)ViewN/AView Earnings Details
8/5/2010Q2 2010($5.82)ViewN/AView Earnings Details
5/6/2010Q1 2010$24.78ViewN/AView Earnings Details
3/25/2010Q4 2009$11.76ViewN/AView Earnings Details
11/3/2009Q3 2009($9.72)ViewN/AView Earnings Details
8/10/2009Q2 2009($6.60)($11.52)ViewN/AView Earnings Details
5/7/2009Q1 2009($10.80)($15.48)ViewN/AView Earnings Details
3/4/2009Q4 2008($26.99)($18.12)ViewN/AView Earnings Details
11/5/2008Q3 2008($23.40)($26.75)ViewN/AView Earnings Details
8/6/2008Q2 2008($25.79)($30.41)ViewN/AView Earnings Details
5/6/2008Q1 2008($24.60)($28.85)ViewN/AView Earnings Details
3/6/2008Q4 2007($26.99)($25.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.06%
Insider Trading History for EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)
Insider Trading History for EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)

EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.003,000View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.002,200View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.